Ubs Asset Management Americas Inc Alnylam Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 736,111 shares of ALNY stock, worth $250 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
736,111
Previous 710,598
3.59%
Holding current value
$250 Million
Previous $167 Million
18.87%
% of portfolio
0.05%
Previous 0.04%
Shares
30 transactions
Others Institutions Holding ALNY
# of Institutions
724Shares Held
111MCall Options Held
966KPut Options Held
853K-
Capital World Investors Los Angeles, CA16.7MShares$5.69 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.44 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$3.24 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.43 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.5 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $41.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...